Clinical Trials
6 trialsNCT03962543 2026-05-06
ReNeu
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2 Active not recruiting
NCT05580770 2026-05-01
Mirdametinib + BGB-3245 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
Phase 1/2 Terminated
NCT03905148 2026-01-07
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
BeOne Medicines
Phase 1 Completed
NCT01347866 2018-10-29
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
Pfizer
Phase 1 Terminated
NCT00147550 2013-09-13
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.
Pfizer
Phase 1/2 Terminated
NCT00174369 2009-03-17
MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 2 Terminated